Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Biotechnology

Healthcare
$92.49 +3.81%

+$3.89 today

Market cap
$6.04B
Beta
0.51
P/E (TTM)
-7.8
EPS (TTM)
-$13.57
52W Low $47.89High $114.99

Volume 0.50M

Average 0.95M

MIRM Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Mirum Pharmaceuticals, Inc.NASDAQ: MIRM

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 63.37M shares rose 27.4% year over year, ahead of the +17.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 7.7% from the prior quarter. Over 3 fiscal years it compounded at +13.9% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +27.4% holds above the trailing-twelve-month pace of +17.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
63.37M+7.7% QoQ
Last fiscal yearDec 2025
50.2M+5.6% YoY
LTMJun 2026
57.35M+17.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.4%——
1 year+5.6%——
3-year CAGR+13.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
50.2M USD
Year-over-year change
+5.6%
4-year CAGR
+13.4%

Weighted Avg Shares (Diluted) vs competitors

How MIRM compares with its peers on the latest reported figures

  • MIRM's LTM Jun 2026 weighted avg shares (diluted) of 57.35M shares is the 5th highest of the 8 companies compared; the peer median is 58.3M shares.
  • Its year-over-year change of +17.8% is the 2nd highest of 8, against a peer median of +2.0%.
  • Over three fiscal years its annual growth of +13.9% compares with a peer median of +9.4%.
MIRM Competitors Peer median
Weighted Avg Shares (Diluted) for MIRM and competitors
Company Period LTM YoY 3-year CAGR
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
ALTAltimmune, Inc.LTM Mar 202698.99M +37.1%+23.4%
TVTXTravere Therapeutics, Inc.LTM Sep 202692.57M +2.0%+11.8%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 202658.3M +1.5%+1.9%
MIRMMirum Pharmaceuticals, Inc.LTM Jun 202657.35M +17.8%+13.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+0.4%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 202625.77M +17.2%+9.4%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
Peer median (excluding MIRM) 58.3M+2.0%+9.4%

Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue19.14M77.06M186.37M336.89M521.31M
Cost of Revenue1.9M12.37M47.04M81.64M100.58M
Gross Profit17.24M64.69M139.34M255.25M420.73M
Gross Margin90.1%83.9%74.8%75.8%80.7%
Research & Development131.43M106.84M102.61M140.63M186.18M
Selling, General & Admin59.22M89.07M145.88M202.22M257.03M
Operating Expenses190.65M195.91M248.49M342.85M443.21M
Depreciation & Amortization975K3.24M10.83M23.63M24.24M
EBITDA(65.39M)(122.85M)(136.49M)(48.97M)17.21M
EBITDA Margin-341.7%-159.4%-73.2%-14.5%3.3%
Operating Income(173.41M)(131.22M)(109.15M)(87.61M)(22.14M)
Operating Margin-906.1%-170.3%-58.6%-26.0%-4.2%
Interest Income366K3.86M13.74M13.79M12.73M
Interest Expense17.59M15.98M15.11M14.31M14.39M
Other Income / Expenses89.46M(10.85M)(53.27M)694K709K
Income Before Tax(83.95M)(142.07M)(162.42M)(86.91M)(21.43M)
Pre-Tax Margin-438.7%-184.4%-87.1%-25.8%-4.1%
Income Tax Expense37K(6.41M)991K1.03M1.94M
Net Income(83.99M)(135.67M)(163.42M)(87.94M)(23.36M)
Net Margin-438.9%-176.0%-87.7%-26.1%-4.5%
EPS (Basic)(2.77)(4.01)(4.00)(1.85)(0.47)
EPS (Diluted)(2.77)(4.02)(4.00)(1.85)(0.47)
Weighted Avg Shares30.32M33.84M40.89M47.52M50.2M
Weighted Avg Shares (Diluted)30.32M33.98M40.89M47.52M50.2M

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Intrinsic Alpha fair value

Locked

Current Price

$92.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.